XENE
NASDAQXenon Pharmaceuticals Inc.
News · 26 weeks63+250%
2026-03-012026-08-23
Mix3390d
- SEC Filings15(45%)
- Insider10(30%)
- Other7(21%)
- Earnings1(3%)
Latest news
25 items- INSIDERDirector Gannon Steven sold $640,550 worth of shares (10,000 units at $64.06), decreasing direct ownership by 84% to 1,870 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- SECSEC Form 10-Q filed by Xenon Pharmaceuticals Inc.10-Q - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECXenon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- PRXenon Reports Q2 2026 Financial Results and Provides Business UpdateNDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with topline data from X-NOVA2 study in MDD expected H1 2027 Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected to complete H2 2026; Phase 1 study underway for second NaV1.7 (XEN1720) candidate for painCash, cash equivalents and marketable securities of $1.2 billion with cash runway into 2029Conference call at 4:30 pm ET today VANCOUVER, BC and BOSTON, MA, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XE
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xenon Pharmaceuticals Inc.SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- PRXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eleven new non-officer employees consisting of an aggregate of 32,758 share options and 19,013 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 30, 2026 and were granted as inducements material to the employees entering into employment w
- PRXenon to Report Q2 2026 Financial Results on August 6, 2026VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its second quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, August 6, 2026. Company Presentation Details: Date:Thursday, August 6, 2026Time:4:30pm ET (1:30pm PT)Webcast:Pre-register hereDial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callersConference ID:5286122 A live webcast of the compan
- PRXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 20,200 share options and 11,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 1, 2026 and were granted as inducements material to the employees entering into e
- INSIDERDirector Patou Gary sold $70,251 worth of shares (1,322 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 24,896 units (SEC Form 4) to cover withholding tax4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERDirector Cannon Gillian sold $63,237 worth of shares (1,190 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 45% to 1,455 units (SEC Form 4) to satisfy tax liability4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- SECSEC Form 144 filed by Xenon Pharmaceuticals Inc.144 - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
- INSIDERDirector Patou Gary converted options into 2,645 shares, increasing direct ownership by 11% to 26,218 units (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERDirector Machado Patrick converted options into 2,645 shares (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERDirector Gover Justin D. converted options into 2,645 shares (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERDirector Garofalo Elizabeth A. converted options into 2,645 shares (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERDirector Gannon Steven converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 12% to 11,870 units (SEC Form 4) to cover withholding tax4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERDirector Cannon Gillian converted options into 2,645 shares (SEC Form 4)4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- INSIDERDirector Svoronos Dawn converted options into 2,645 shares and covered exercise/tax liability with 1,416 shares, increasing direct ownership by 5% to 26,229 units (SEC Form 4) to satisfy withholding tax4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
- SECSEC Form S-8 POS filed by Xenon Pharmaceuticals Inc.S-8 POS - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECSEC Form S-8 POS filed by Xenon Pharmaceuticals Inc.S-8 POS - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECSEC Form S-8 POS filed by Xenon Pharmaceuticals Inc.S-8 POS - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECSEC Form S-8 POS filed by Xenon Pharmaceuticals Inc.S-8 POS - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
- SECSEC Form S-8 POS filed by Xenon Pharmaceuticals Inc.S-8 POS - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
XENE FAQ
7 questionsWhat does Xenon Pharmaceuticals Inc. do?
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in...Where does XENE stock trade?
Xenon Pharmaceuticals Inc. (XENE) is listed on NASDAQ.What sector and industry is XENE in?
Xenon Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Xenon Pharmaceuticals Inc. go public?
Xenon Pharmaceuticals Inc. (XENE) completed its IPO in 2014.What are analysts saying about XENE?
Xenon Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-02-24. Recent price targets cluster around $4800.00.What companies are similar to XENE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare XENE side-by-side with any of them on Quantisnow.How can I track XENE on Quantisnow?
Quantisnow aggregates Xenon Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XENE to receive live email and push alerts on every new disclosure.